Caplin Point Laboratories Limited has announced its financial results for the quarter and half year ended September 30, 2026. The company reported a 13.8% year-on-year increase in Profit After Tax (PAT) for Q2 FY27, reaching ₹182.4 Crores. For the half year ended September 30, 2026, PAT increased by 16.2% to ₹361.4 Crores. Revenue from operations also showed significant growth, with a 17.9% YoY increase in Q2 FY27 and an 18.8% YoY increase in H1 FY27.
Caplin Point Laboratories Announces Robust Q2 and H1 FY27 Financial Performance
Caplin Point Laboratories Limited has disclosed its unaudited financial results for the second quarter and the first half of the financial year 2027, ending September 30, 2026. The company has demonstrated strong growth across key financial metrics, indicating a positive trajectory for the business.
Q2 FY27 Highlights
- Revenue from Operations: Increased by 17.9% to ₹629.8 Crores for Q2 FY27, compared to ₹534.0 Crores in Q2 FY26.
- Total Revenue: Rose by 17.5% to ₹663.1 Crores in Q2 FY27 from ₹564.4 Crores in the corresponding period of the previous year.
- Gross Profit: Grew by 20.8% to ₹391.2 Crores.
- EBITDA: Saw a substantial increase of 16.8% to ₹256.5 Crores.
- Profit Before Tax (PBT): Increased by 15.8% to ₹232.8 Crores.
- Profit After Tax (PAT): Grew by 13.8% year-on-year to ₹182.4 Crores.
- Gross Profit Margin: Improved to 62.1% from 60.6% in Q2 FY26.
- EBITDA Margin: Stood at 38.7%.
- PAT Margin: Reported at 27.5%.
H1 FY27 Performance
- Revenue from Operations: Increased by 18.8% to ₹1,240.2 Crores for H1 FY27, compared to ₹1,044.3 Crores in H1 FY26.
- Total Revenue: Rose by 19.1% to ₹1,307.0 Crores in H1 FY27.
- Gross Profit: Grew by 18.4% to ₹756.3 Crores.
- EBITDA: Increased by 19.8% to ₹503.5 Crores.
- Profit Before Tax (PBT): Increased by 18.8% to ₹458.1 Crores.
- Profit After Tax (PAT): Grew by 16.2% year-on-year to ₹361.4 Crores.
- Gross Profit Margin: Stood at 61.0%.
- EBITDA Margin: Reported at 38.5%.
- PAT Margin: Stood at 27.7%.
Other Consolidated Financial Highlights
- Cash Flow from Operations: Was ₹205 Crores in H1 FY27.
- Free Cash Flow: Amounted to ₹70 Crores in H1 FY27.
- Free Cash Reserves: Stood at ₹1,534 Crores as of September 30, 2026.
- Liquid Assets: Were ₹2,967 Crores.
- Inventories: Stood at ₹544 Crores as of September 30, 2026.
- Receivables: Stood at 129 days.
The company’s management highlighted disciplined, broad-based growth in H1 FY27, with total revenue crossing ₹1,300 Crores and EBITDA crossing ₹500 Crores, both up close to 20% year-on-year. The company continues to strengthen its Latin American business with new tenders and expansion into oncology sales in Mexico. The US business, through Caplin Steriles USA, has surpassed its full FY26 sales in the first six months of its second year, demonstrating rapid customer acquisition. Significant reinvestment is being made into new capacity and capabilities, including oncology, APIs, and digitalization, supported by strong free cash reserves.
Source: BSE
